Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Puma Biotechnology Inc (PBYI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: PBYI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Year Target Price $3
Year Target Price $3
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Under performing |
| 1 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 6.07% | Avg. Invested days 31 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 165.29M USD | Price to earnings Ratio 4.27 | 1Y Target Price 3 |
Price to earnings Ratio 4.27 | 1Y Target Price 3 | ||
Volume (30-day avg) - | Beta 1.28 | 52 Weeks Range 2.23 - 4.13 | Updated Date 06/29/2025 |
52 Weeks Range 2.23 - 4.13 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.78 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 16.36% | Operating Margin (TTM) 8.66% |
Management Effectiveness
Return on Assets (TTM) 11.35% | Return on Equity (TTM) 51.41% |
Valuation
Trailing PE 4.27 | Forward PE 7.75 | Enterprise Value 133841849 | Price to Sales(TTM) 0.71 |
Enterprise Value 133841849 | Price to Sales(TTM) 0.71 | ||
Enterprise Value to Revenue 0.58 | Enterprise Value to EBITDA 2.45 | Shares Outstanding 49638100 | Shares Floating 38066461 |
Shares Outstanding 49638100 | Shares Floating 38066461 | ||
Percent Insiders 15.87 | Percent Institutions 64.96 |
Analyst Ratings
Rating 2.5 | Target Price 3 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Puma Biotechnology Inc
Company Overview
History and Background
Puma Biotechnology Inc. was founded in 2010. It focuses on the development and commercialization of innovative products to enhance cancer care. A significant milestone was the FDA approval of Nerlynx (neratinib) in 2017. The company has evolved from a clinical-stage biotech to a commercial entity.
Core Business Areas
- Oncology Therapeutics: Puma focuses on developing and commercializing therapies for cancers that are driven by HER2 mutations, particularly in breast cancer.
Leadership and Structure
Alan H. Auerbach is the Chairman, CEO and President. The organizational structure is typical of a biotech company, with departments focusing on R&D, clinical trials, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Nerlynx (neratinib): Nerlynx is an oral kinase inhibitor indicated for extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. Nerlynx generated $197 million in 2023 revenue. Competitors include drugs that also target HER2-positive breast cancer, such as Enhertu (Daiichi Sankyo/AstraZeneca) and Kadcyla (Roche).
Market Dynamics
Industry Overview
The oncology therapeutics market is highly competitive and driven by technological advancements, increasing cancer incidence, and unmet medical needs. The HER2-positive breast cancer segment is a significant area of focus.
Positioning
Puma Biotechnology is positioned as a company focused on HER2-positive breast cancer with Nerlynx, but competes against larger, more established pharmaceutical companies with broader portfolios.
Total Addressable Market (TAM)
The global HER2-positive breast cancer therapeutics market is projected to reach over $10 billion. Puma Biotechnology captures a small portion of this market with its focus on extended adjuvant treatment.
Upturn SWOT Analysis
Strengths
- Approved HER2-targeted therapy (Nerlynx)
- Experienced management team
- Focus on a specific cancer subtype
Weaknesses
- Sole reliance on Nerlynx
- Limited pipeline
- Competition from larger pharmaceutical companies
Opportunities
- Expansion of Nerlynx into new indications
- Strategic partnerships for pipeline development
- Geographic expansion into new markets
Threats
- Competition from newer HER2-targeted therapies
- Patent expirations
- Regulatory changes affecting drug approvals
Competitors and Market Share
Key Competitors
- AZN
- ROSY
- GILD
Competitive Landscape
Puma Biotechnology faces significant competition from larger pharmaceutical companies with greater resources and broader product portfolios. Puma's advantage lies in its focus on HER2-positive breast cancer and Nerlynx's unique extended adjuvant treatment indication.
Growth Trajectory and Initiatives
Historical Growth: Puma experienced initial growth following Nerlynx approval but has since faced challenges in maintaining momentum due to competitive pressures.
Future Projections: Analyst projections depend heavily on Nerlynx's performance and potential new indications. Growth is expected to be moderate.
Recent Initiatives: Puma is exploring new clinical trials and potential collaborations to expand Nerlynx's use and develop its pipeline.
Summary
Puma Biotechnology is a company focused on HER2-positive breast cancer, relying mainly on the drug Nerlynx. It faces competitive pressures from larger pharma companies and needs to expand Nerlynx's application or diversify its pipeline. Financial performance is mixed, with declining revenue and efforts to improve profitability. Future success depends on managing costs and finding new market opportunities.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q)
- Analyst reports
- Press releases
- Company Investor Relations page
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be based on individual risk tolerance and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Puma Biotechnology Inc
Exchange NASDAQ | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2012-04-24 | Founder, Chairman, President, CEO & Secretary Mr. Alan H. Auerbach | ||
Sector Healthcare | Industry Biotechnology | Full time employees 172 | |
Full time employees 172 | |||
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.